CA3152789A1 - Conjugated hepcidin mimetics - Google Patents
Conjugated hepcidin mimetics Download PDFInfo
- Publication number
- CA3152789A1 CA3152789A1 CA3152789A CA3152789A CA3152789A1 CA 3152789 A1 CA3152789 A1 CA 3152789A1 CA 3152789 A CA3152789 A CA 3152789A CA 3152789 A CA3152789 A CA 3152789A CA 3152789 A1 CA3152789 A1 CA 3152789A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- subject
- pharmaceutically acceptable
- isovaleric acid
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895201P | 2019-09-03 | 2019-09-03 | |
| US62/895,201 | 2019-09-03 | ||
| US202062983515P | 2020-02-28 | 2020-02-28 | |
| US62/983,515 | 2020-02-28 | ||
| US202063020945P | 2020-05-06 | 2020-05-06 | |
| US63/020,945 | 2020-05-06 | ||
| US202063059747P | 2020-07-31 | 2020-07-31 | |
| US63/059,747 | 2020-07-31 | ||
| PCT/US2020/049244 WO2021046246A1 (en) | 2019-09-03 | 2020-09-03 | Conjugated hepcidin mimetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3152789A1 true CA3152789A1 (en) | 2021-03-11 |
Family
ID=74681239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3152789A Pending CA3152789A1 (en) | 2019-09-03 | 2020-09-03 | Conjugated hepcidin mimetics |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20220372099A1 (https=) |
| EP (2) | EP4025592B1 (https=) |
| JP (2) | JP7831841B2 (https=) |
| KR (1) | KR20220075343A (https=) |
| CN (1) | CN114729022A (https=) |
| AU (1) | AU2020343328B2 (https=) |
| BR (1) | BR112022003999A2 (https=) |
| CA (1) | CA3152789A1 (https=) |
| DK (1) | DK4025592T3 (https=) |
| ES (1) | ES3058577T3 (https=) |
| FI (1) | FI4025592T3 (https=) |
| IL (1) | IL291030A (https=) |
| MX (1) | MX2022002633A (https=) |
| PH (1) | PH12022550510A1 (https=) |
| PL (1) | PL4025592T3 (https=) |
| WO (1) | WO2021046246A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| HRP20211448T1 (hr) | 2014-05-16 | 2021-12-24 | Protagonist Therapeutics, Inc. | Alfa4beta7 integrin tioeter peptidni antagonisti |
| CN107206254B (zh) | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| US20190002503A1 (en) | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| WO2020014646A1 (en) | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| AU2021209086A1 (en) | 2020-01-15 | 2022-08-04 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| CA3167751A1 (en) | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| JP7397239B2 (ja) | 2020-11-20 | 2023-12-12 | ヤンセン ファーマシューティカ エヌ．ベー． | インターロイキン－２３受容体のペプチド阻害剤の組成物 |
| AU2022249095A1 (en) * | 2021-04-01 | 2023-10-12 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| IL309166A (en) * | 2021-06-14 | 2024-02-01 | Protagonist Therapeutics Inc | Pasidine mimesis for the treatment of hereditary hemochromatosis |
| EP4370146A4 (en) | 2021-07-14 | 2025-05-21 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of the interleukin-23 receptor |
| EP4472996A4 (en) * | 2022-02-02 | 2025-11-26 | Protagonist Therapeutics Inc | Conjugated hepcidin mimetics |
| EP4472995A4 (en) * | 2022-02-02 | 2025-11-19 | Protagonist Therapeutics Inc | Conjugated hepcidin mimetics |
| WO2024011188A1 (en) * | 2022-07-07 | 2024-01-11 | Protagonist Therapeutics, Inc. | Combination therapy for treatment of iron overload diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| CZ20013018A3 (cs) | 1999-03-17 | 2002-02-13 | Novo Nordisk A/S | Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina |
| US7094785B1 (en) * | 2002-12-18 | 2006-08-22 | Cornell Research Foundation, Inc. | Method of treating polycythemia vera |
| CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| EP3129040A4 (en) | 2014-04-07 | 2018-03-21 | La Jolla Pharmaceutical Company | Hepdicin mimetic peptides and uses thereof |
| WO2015200916A2 (en) | 2014-06-27 | 2015-12-30 | Protagonist Therapeutics, Inc. | Hepcidin and mini-hepcidin analogues and uses therof |
| UA123219C2 (uk) | 2015-10-23 | 2021-03-03 | Віфор (Інтернаціональ) Аґ | Інгібітори феропортину |
| US20190002503A1 (en) | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| EP3509621A4 (en) | 2016-09-06 | 2020-06-17 | La Jolla Pharmaceutical Company | METHODS OF TREATING IRON OVERLOAD |
| WO2018128828A1 (en) * | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Novel hepcidin mimetics and uses thereof |
| CA3089868A1 (en) * | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
-
2020
- 2020-09-03 PH PH1/2022/550510A patent/PH12022550510A1/en unknown
- 2020-09-03 WO PCT/US2020/049244 patent/WO2021046246A1/en not_active Ceased
- 2020-09-03 FI FIEP20860676.4T patent/FI4025592T3/fi active
- 2020-09-03 EP EP20860676.4A patent/EP4025592B1/en active Active
- 2020-09-03 DK DK20860676.4T patent/DK4025592T3/da active
- 2020-09-03 US US17/639,138 patent/US20220372099A1/en not_active Abandoned
- 2020-09-03 US US17/011,844 patent/US20210061872A1/en active Pending
- 2020-09-03 CA CA3152789A patent/CA3152789A1/en active Pending
- 2020-09-03 CN CN202080076351.4A patent/CN114729022A/zh active Pending
- 2020-09-03 ES ES20860676T patent/ES3058577T3/es active Active
- 2020-09-03 JP JP2022540618A patent/JP7831841B2/ja active Active
- 2020-09-03 EP EP25211675.1A patent/EP4706671A3/en active Pending
- 2020-09-03 MX MX2022002633A patent/MX2022002633A/es unknown
- 2020-09-03 PL PL20860676.4T patent/PL4025592T3/pl unknown
- 2020-09-03 AU AU2020343328A patent/AU2020343328B2/en active Active
- 2020-09-03 BR BR112022003999A patent/BR112022003999A2/pt unknown
- 2020-09-03 KR KR1020227011086A patent/KR20220075343A/ko active Pending
-
2022
- 2022-03-01 IL IL291030A patent/IL291030A/en unknown
-
2025
- 2025-07-31 JP JP2025128508A patent/JP2025163134A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022002633A (es) | 2022-06-02 |
| AU2020343328A1 (en) | 2022-04-07 |
| US20220372099A1 (en) | 2022-11-24 |
| AU2020343328B2 (en) | 2026-04-09 |
| ES3058577T3 (en) | 2026-03-11 |
| CN114729022A (zh) | 2022-07-08 |
| FI4025592T3 (fi) | 2026-01-30 |
| JP2025163134A (ja) | 2025-10-28 |
| EP4025592B1 (en) | 2025-10-29 |
| PL4025592T3 (pl) | 2026-03-16 |
| EP4025592A1 (en) | 2022-07-13 |
| KR20220075343A (ko) | 2022-06-08 |
| EP4706671A3 (en) | 2026-04-01 |
| DK4025592T3 (da) | 2026-02-09 |
| IL291030A (en) | 2022-05-01 |
| WO2021046246A1 (en) | 2021-03-11 |
| PH12022550510A1 (en) | 2023-09-04 |
| EP4025592A4 (en) | 2023-08-02 |
| JP7831841B2 (ja) | 2026-03-17 |
| EP4706671A2 (en) | 2026-03-11 |
| BR112022003999A2 (pt) | 2022-05-31 |
| US20210061872A1 (en) | 2021-03-04 |
| JP2022546878A (ja) | 2022-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020343328B2 (en) | Conjugated hepcidin mimetics | |
| US12269856B2 (en) | Hepcidin analogues and uses thereof | |
| EP4188412A1 (en) | Conjugated hepcidin mimetics | |
| WO2017117411A1 (en) | Analogues of hepcidin mimetics with improved in vivo half lives | |
| EP3749345A1 (en) | Conjugated hepcidin mimetics | |
| WO2022212696A1 (en) | Conjugated hepcidin mimetics | |
| WO2022212698A1 (en) | Conjugated hepcidin mimetics | |
| EA048412B1 (ru) | Конъюгированные миметики гепсидина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240830 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240830 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240830 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240903 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240903 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20250219 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20250219 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250219 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250401 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250409 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250516 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250516 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250521 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250702 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250702 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250807 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250807 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250807 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250820 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250903 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260211 |